Overview

SPACE Trial: Pyridostigmine vs Placebo in SMA Types 2, 3 and 4

Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
A trial investigating the effects of pyridostigmine (mestinon) versus a placebo in a double-blind cross over trial in patients with hereditary proximal spinal muscular atrophy (SMA) types 2, 3 and 4.
Phase:
Phase 2
Details
Lead Sponsor:
UMC Utrecht
Treatments:
Pyridostigmine Bromide